Literature DB >> 34320284

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

Gil D Rabinovici1.   

Abstract

Entities:  

Year:  2021        PMID： 34320284     DOI： 10.1056/NEJMp2111320

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  28 in total

Review 1.  Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities.

Authors:  Shaomin Li; Andrew M Stern
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

2.  Disease modification is not all - we need symptomatic therapies for Alzheimer disease.

Authors:  Jeffrey Cummings
Journal:  Nat Rev Neurol       Date:  2022-01       Impact factor: 42.937

3.  Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer's Disease.

Authors:  Chun-Gu Hong; Meng-Lu Chen; Ran Duan; Ming Lu; Hui Xie; Zheng-Zhao Liu; Xin Wang; Zhi-Lin Pang; Li-Te Ge
Journal:  Mol Neurobiol       Date:  2022-09-29       Impact factor: 5.682

4.  Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.

Authors:  Consuelo H Wilkins; Charles C Windon; Peggye Dilworth-Anderson; Justin Romanoff; Constantine Gatsonis; Lucy Hanna; Charles Apgar; Ilana F Gareen; Carl V Hill; Bruce E Hillner; Andrew March; Barry A Siegel; Rachel A Whitmer; Maria C Carrillo; Gil D Rabinovici
Journal:  JAMA Neurol       Date:  2022-10-03       Impact factor: 29.907

Review 5.  The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.

Authors:  Marianne Chapleau; Leonardo Iaccarino; David Soleimani-Meigooni; Gil D Rabinovici
Journal:  J Nucl Med       Date:  2022-06       Impact factor: 11.082

6.  The dense-core plaques of Alzheimer's disease are granulomas.

Authors:  Greg Lemke; Youtong Huang
Journal:  J Exp Med       Date:  2022-06-22       Impact factor: 17.579

7.  Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors:  Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal:  Neurology       Date:  2022-02-23       Impact factor: 11.800

Review 8.  The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.

Authors:  Eric Karran; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2022-02-17       Impact factor: 112.288

Review 9.  GRK5 Deficiency Causes Mild Cognitive Impairment due to Alzheimer's Disease.

Authors:  William Z Suo
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

10.  Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.

Authors:  Jiansong Fang; Pengyue Zhang; Quan Wang; Chien-Wei Chiang; Yadi Zhou; Yuan Hou; Jielin Xu; Rui Chen; Bin Zhang; Stephen J Lewis; James B Leverenz; Andrew A Pieper; Bingshan Li; Lang Li; Jeffrey Cummings; Feixiong Cheng
Journal:  Alzheimers Res Ther       Date:  2022-01-10       Impact factor: 8.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.